Study drug follow-up for LDL reduction in high-risk cholesterol patients
Treatments studied
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This Phase 3 study looks at the long-term safety and benefit of OLE LIB003 for people with very high cholesterol or heart disease risk who still need lower LDL (“bad cholesterol”). It’s likely a continuation study for participants who already did earlier LIB003 Phase 3 trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have successfully completed one of the earlier Phase 3 LIB003 base studies (listed in the criteria) with no study-drug–related serious side effects.
- You must sign consent before any study-specific testing or procedures.
- If you could become pregnant, you must use very reliable birth control and have a negative urine pregnancy test on Day 1 before taking the dose.
- You must be willing to keep a stable cholesterol-lowering plan and diet (including your current medications) during the study.
- You must not have used certain cholesterol medicines after the base study, such as PCSK9 antibody injections, mipomersen, lomitapide, or specific related treatments (timing rules apply).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is checking the long-term safety and how well a new injectable medicine (lerodalcibep) works to lower cholesterol in children and teens with familial hypercholesterolemia (an inherited condition causing very high cholesterol). It's for those who already finished an earlier study of this same medicine.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
This study tests an experimental drug (QLC7401) that may help lower LDL ('bad') cholesterol in people who already have high cholesterol or mixed hyperlipidemia. If you're on stable cholesterol medication but still need more lowering, this trial could offer another option.
This study tests a new investigational medicine (QLC7401) that aims to lower LDL ('bad') cholesterol when added to your current cholesterol-lowering therapy. If you are already on a statin but your cholesterol is still not low enough, this trial might help you reach your goals.
This trial tests a new medicine that aims to lower LDL (bad) cholesterol in healthy adults. It will help doctors understand how the medicine works in the body and how safe it is.
This study tests whether an educational program can help people with high cholesterol and heart disease get their LDL cholesterol levels lower. It involves watching online videos and working with your doctor to adjust treatments.
Hear when a new Familial Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.